Frontier IP Group (AIM:FIPP), a specialist in commercialising intellectual property, announced that portfolio company inSignals Neurotech has received a €317,762 grant co-financed by the European Union through Portugal's NORTE 2030 programme.
Frontier IP holds a 32.9% equity stake in inSignals.
The grant will fund the extension of inSignals' proprietary algorithms to operate remotely via third-party consumer wearable devices, including smartwatches and smart rings, enabling continuous monitoring of Parkinson's disease outside clinical settings.
The company's technology has been validated across more than 200 patients in an international multi-centre clinical study, and inSignals holds patents covering rigidity quantification methods, an objective measure of a key Parkinson's symptom.
In parallel, inSignals is launching a mobile application for patients and caregivers, funded by a separate PRR Green Vouchers grant, to support symptom monitoring and clinician communication.
InSignals is also conducting a seed fundraising round focused on medical regulatory compliance and international expansion.
"This funding allows us to take a significant step towards that goal by bringing our proprietary algorithms beyond specialised clinical settings and into everyday wearable devices," said inSignals co-founder and chief science officer João Paulo Cunha.
